

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



偉俊 生物 科技 有限 公司

Wai Chun Bio-Technology Limited

(Incorporated in the Cayman Islands with limited liabilities)

(Stock code: 660)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO TENANCY AGREEMENT

Reference is made to the announcement of the Company dated 5 August 2022 (the “Announcement”) in relation to a connected transaction relating to New Tenancy Agreement. Terms used herein shall have the same meanings as defined in the Announcement unless otherwise stated.

As disclosed in the Announcement, on 5 August 2022, the Tenant entered into the New Tenancy Agreement with the Landlord for the lease of the Premises for a rental term of three years. As the Landlord is a connected person of the Company, the transaction in relation to the New Tenancy Agreement was disclosed as a connected transaction under Chapter 14A of the Listing Rules.

The Board wishes to announce that none of the Directors had any material interest in the New Tenancy Agreements, and accordingly no Director was required to abstain from voting on the resolutions in relation to the New Tenancy Agreements.

By Order of the Board
Wai Chun Bio-Technology Limited
Chan Cheuk Ho
Executive Director

Hong Kong, 8 August 2022

As at the date of this announcement, the Board comprises one executive Director, namely Mr. Chan Cheuk Ho, and two independent non-executive Directors, namely Mr. Wan Bo and Mr. Hau Pak Man.